AzTrials
AzTrials

Premature Exit After Colorectal SurgeryColo-SENSIUMNCT05610995

Feasibility Study of Early Return-home After Colorectal Surgery Using a SENSIUM® Vital Parameter Monitoring Device

A study testing SENSIUM Patch in people with Premature Exit After Colorectal Surgery, run by University Hospital, Grenoble at 7 sites in France.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The principal aim of this study is to evaluate the impact on length of stay of a return-to-home monitoring device versus enhanced rehabilitation after bowel resection surgery with anastomosis. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Premature Exit After Colorectal Surgery
What is being tested?
SENSIUM Patch
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
6 participants
Where
7 sitesFrance
Study dates
22 Jul 2023to 8 Oct 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥ 18 years
  • ASA score 1-3
  • Colonic or rectal resection with anastomosis
  • Minimally invasive surgery
  • Patient living close to the hospital (<1 hour drive)
  • Patient accompanied for 48 hours
Show all 21Show fewer
  • Body Mass Index < 40
  • Patient information and signature of consent
  • Patient affiliated to a social insurance plan
  • A pregnancy test must be performed before inclusion in women of childbearing age.
  • Non-inclusion Criteria:
  • Socially isolated patient and/or no 3G cell signal
  • Severe comorbidities defined as any of these characteristics:
  • Severe malnutrition (albumin <30g/l)
  • Severe anemia < 80 g/dl
  • Insulin-dependent diabetes type 1
  • Patient under anticoagulation f. Severe renal insufficiency
  • History of psychiatric illness with medication requirements
  • Persons referred to in articles L1121-5 to L1121-8 of the CSP (corresponds to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of liberty by judicial or administrative decision, persons under legal protection)
  • Patient not wishing to enter the study
  • Patient in a period of exclusion from another study or ongoing participation in an interventional study

Who cannot join

  • Stoma preparation
  • Per operative conversion to laparotomy
  • CHUNG score > 8

Trial locations and contacts

7 sites in 1 country.

7 sites in 1 country

France7 sites
  • Chu Amiens

    Amiens

  • CHU Angers

    Angers

  • Clinique TIVOLI

    Bordeaux

  • Chru Brest

    Brest

  • CHU Grenoble Alpes

    Grenoble

  • Institut Paoli Calmettes

    Marseille

  • Chu Nantes

    Nantes

Other trials in France

About this study

The principal aim of this study is to evaluate the impact on length of stay of a return-to-home monitoring device versus enhanced rehabilitation after bowel resection surgery with anastomosis.

The device SENSIUM is a tool to monitor vital signs (respiratory rate, heart rate and temperature) by applying a connected skin patch in order to detect complications early.

Being tested
SENSIUM Patch

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SENSIUM PatchDevice

    The SENSIUM device is a tool to monitor vital signs by applying a connected skin patch whose objective is to detect complications early. The health data is transmitted to the practitioner and in case of disturbance of the parameters, an alert is sent. The patient can be called for consultation or hospitalization if necessary. This device has been tested under real clinical conditions in surgical units. The continuous monitoring of vital signs resulted in earlier detection of sepsis, earlier administration of antibiotics, shorter average length of stay and lower 30-day readmission rates.

Study groups in NCT05610995
Study groupRoleWhat they receive
SENSIUM GroupExperimentalPatients in the experimental group will be discharged with the device after an assessment on Day 1.
Receives: Device: SENSIUM Patch
ERAS standard GroupNo interventionPatients in the control group will receive the usual ERAS (conventional hospitalization for clinicobiological monitoring).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluating the impact on length of stay of a return-to-home monitoring device versus enhanced rehabilitation after bowel resection surgery with anastomosis

    Overall length of stay of the patient (index stay, and possible re-hospitalizations)

    Measured: at Day 30

Secondary outcomes (9)
  1. Assess transit recovery

    Time of resumption of transit formalized by the resumption of gas, the time being calculated between the closure of the skin and the first gas in hours

    Measured: at Day 1

  2. Assess pain

    Pain, by visual analog scale (0-10)

    Measured: at Day 0, Day 1, Day 2, Day 3, Day 4, Day 5 and Day 30

  3. Assess opioid use

    5-day opioid consumption rate

    Measured: at Day 5

  4. Evaluate the complication rate

    Presence of a complication according to the Clavien Dindo classification

    Measured: at Day 30 according to the postoperative management performed

  5. Evaluate the rate of re-hospitalization performed

    Presence of a rehospitalization between the post-surgical hospital discharge and Day 30

    Measured: To the post-surgical hospital discharge at Day 30

  6. Assess the rate of unscheduled visits

    Presence of an unscheduled consultation at Day 30 post-surgery

    Measured: at Day 30

  7. Assess the patient's quality of life and overall satisfaction

    EuroQol 5D 3L standardized scale score (overall satisfaction) at pre-inclusion, Day 1, Day 5 and Day 30 post-surgery visit

    Measured: at Day 30

  8. Evaluate the cost of care

    Cost analysis (hospitalizations, consultations, re-interventions, time off work, transportation and SENSIUM system costs)

    Measured: To Day 1 at the end of study

  9. Evaluate the evolution of vital parameters

    Trend analysis of vital parameters

    Measured: To Day 1 at the end of study

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Nov 2022
  2. Study start22 Jul 2023
  3. Primary completion8 Oct 2024
  4. Study completion8 Oct 2024

Why it stopped: recruitment faisibility

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
Prospective, multicenter, randomized, two-arm, parallel, open-label, interventional controlled trial with masked outcome assessment (PROBE design)
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
6 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05610995
Sponsor's protocol ID
38RC21.0379
Acronym
Colo-SENSIUM
Status last verified
Dec 2025
First submitted
20 Sep 2022
Last updated
29 Dec 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing SENSIUM Patch in people with Premature Exit After Colorectal Surgery, run by University Hospital, Grenoble at 7 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 21 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 29 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: recruitment faisibility). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluating the impact on length of stay of a return-to-home monitoring device versus enhanced rehabilitation after bowel resection surgery with anastomosis (time frame: at Day 30). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in